



Because
Family Matters

PT Bundamedik Tbk


Earnings Call – 9M24 Results

Nov 2024






Leading Provider in Specialized Healthcare Services since 1973



Bundamedik Tbk (BMHS) Ecosystem



Expanding Presence

10 HOSPITALS



12 IVF CLINICS



25 LABORATORIES



3k++ CLINICS NETWORK (KLINIK PINTAR)



126 FERTILITY CLINICS NETWORK (KFI)





Our commitment to serve better
Because Family Matters

9M24 Key Highlights

1



Consol Revenue

+5%

vs 9M23

+12% # of Outpatients
+26% # of IP Days
+9% # of Surgeries
+25% # of Lab Tests

2



Consolidated Gross Margin

55%

Higher +1% vs 9M23

3



EBITDA

+21%

vs 9M23

Net Profit

+123%

vs 9M23

4



New Hospitals

+62%

Net Revenue
vs 9M23

+1975%

EBITDA improvement
vs 9M23

#HolisticFamilyCare

9M24 Results

Financial & Operational Performance


	HIGHLIGHTS OF CONSOLIDATED RESULT					
	2Q24	3Q24	QoQ (%)	9M23	9M24	YoY (%)
1 OPERATIONALS ('000)						
# Outpatient	148.3	153.7	4%	410.7	460.5	12%
# Inpatient Days	31.2	28.9	-8%	73.6	92.6	26%
# Inpatient Admission	11.7	11.1	-5%	31.2	35.1	12%
# Surgery	3.6	3.8	5%	10.2	11.1	9%
# Beds	631	631	0%	631	631	0%
BOR (%)	54%	50%		43%	54%	
BOR Existing (%)	60%	56%		55%	61%	
BOR New (%)	68%	61%		29%	64%	
# IVF Cycles	1.1	1.2	4%	3.8	3.7	-3%
# Lab Test (Diagnos)	205.2	206.2	0%	509.5	639.3	25%
2 PROFIT LOSS (Rp Bn)						
Gross Revenue	371	372	0%	1,099	1,157	5%
Net Revenue	315	315	0%	941	986	5%
Gross Profit	175	175	0%	512	545	6%
<i>GPM (%) to net</i>	<i>56%</i>	<i>56%</i>		<i>54%</i>	<i>55%</i>	
3 EBITDA	52	52	0%	145	175	21%
<i>EBITDA Margin (%) to net</i>	<i>17%</i>	<i>17%</i>		<i>15%</i>	<i>18%</i>	
Net Profit	1.0	1.5	55%	9.0	20.2	123%
<i>NPM (%)</i>	<i>0%</i>	<i>0%</i>		<i>1%</i>	<i>2%</i>	
NP attributable to:						
Owners of the parent	0.1	0.8	732%	6.2	11.8	90%
Non-controlling interests	0.9	0.7	-21%	2.8	8.4	199%

Key Notes


- Core Business in 9M24**
 - Hospitals metrics:** Overall positive growth in #Outpatients, #Surgery, and #IP Days
 - Morula** - # of cycles declined by -3% due to flat market growth but 3Q has shown improvement QoQ
 - Diagnos** - Growth in # of lab test volume by +25% vs 9M23
- 9M24 Gross Revenue improved by +5% YoY** due to:
 - Improvement operational metrics resulted growth in all business units (Hospital +4% YoY; Morula +3% YoY; Diagnos +15% YoY)
- 9M24 EBITDA grew by +21% YoY** due to:
 - EBITDA margin improvement in 9M24 by +3% resulted from impact of various initiatives in early 2024.

Hospital Volume


OUTPATIENTS



IP ADMISSION



IP DAYS



SURGERIES




All units in '000

Financial Performance

Consolidated


NET REVENUE (Rp B)

Net Core Revenue
Net Covid Revenue



EBITDA (Rp B, % Margin)


EBITDA Margin
Covid EBITDA
Core EBITDA




Balance Sheet

Remains healthy


CASH VS DEBT
(Rp B)



NET DEBT-TO-EBITDA
(x)




WORKING CAPITAL DAYS



IVF Cycles

OF IVF CYCLES ('000)




Diagnos

Focusing on genomic testing

OF TESTS ('000)

Covid Non Covid




+25% ↑

YoY Number of Test Volume



REVENUE (in bn rupiah)

Covid Revenue Genomic Revenue Others Test



+15% ↑


YoY Revenue



Promising Genomic revenue YoY increased by 53% YoY, contributing 17% of revenue


Strengthening Our Core

Strengthening Our COEs



Bunda General Hospital
Bunda Women & Children Hospital
Jakarta


Revenue Per payor in Hospital:



Hospitals improvement perspective:

- Increased **+2.5pps** in **BPJS payor** as our new hospitals mainly serves BPJS
- Bunda well-known for OBGYN and Pediatric specialization, this year we grow other COEs
- Revenue contribution from non OBGYN and Pediatric in 9M24 was 48% (**+9pps higher** than 9M23)

Revenue Per Specialistic:



Ensuring Standardized Quality Process



2024 Update & Initiatives

2024 Key Initiatives

1

Optimize and standardize
pricing guideline

2

Improving overall **medical services, facilities, branding and patient experience**

3

Central procurement for
pharma and consumables

4

Implement **data integration**
throughout BMHS group

5

Establish **culture and employee engagement**




As of 31 September 2024,

41%

Of existing Bunda's patients (non BPJS)
have registered and used OneBunda

Most Frequently Used
Features is Janji Temu that
generate

~107K
Transactions



Because *Family Matters*



PT Bundamedik Tbk

Jl. Teuku Cik Ditiro No. 28, Menteng, Jakarta 10350 – Indonesia
(62-21) 3192-3344